# Comparison of Ranibizumab Monotherapy and Ranibizumab Combination Therapies in Recurrent or Persistent Choroidal Neovascularization Secondary to Age-related Macular Degeneration

> **NCT01162746** · PHASE2 · COMPLETED · sponsor: **Medical University of Vienna** · enrollment: 40 (actual)

## Conditions studied

- Age-Related Macular Degeneration
- Neovascularization, Choroidal

## Interventions

- **DRUG:** Intravitreal dexamethasone and intravitreal ranibizumab
- **DRUG:** Intravitreal ranibizumab

## Key facts

- **NCT ID:** NCT01162746
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2015-06
- **Final completion:** 2015-12
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2017-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01162746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01162746, "Comparison of Ranibizumab Monotherapy and Ranibizumab Combination Therapies in Recurrent or Persistent Choroidal Neovascularization Secondary to Age-related Macular Degeneration". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01162746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*